Drugs and Devices

FDA approves Lucentis to treat diabetic retinopathy

On February 6, the U.S. Food and Drug Administration (FDA) expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy in patients with diabetic macular edema. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares